Latest Conference Articles

June 4th 2016, 10:03pm

ASCO Annual Meeting

A regimen consisting of carfilzomib, pomalidomide, and dexamethasone merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide in the earlier stages of disease.

June 4th 2016, 9:01pm

ASCO Annual Meeting

Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.

June 4th 2016, 4:22am

ASCO Annual Meeting

Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.

June 4th 2016, 4:21am

ASCO Annual Meeting

Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).

June 4th 2016, 4:18am

ASCO Annual Meeting

The CDK4/6 inhibitor abemaciclib induced a response rate of nearly 20% in heavily pretreated patients with refractory, HR-positive, HER2-negative advanced breast cancer, according to findings from the phase II MONARCH 1 trial.

June 4th 2016, 3:54am

ASCO Annual Meeting

The anti-CD38 monoclonal antibody isatuximab showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma.

June 4th 2016, 3:38am

ASCO Annual Meeting

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

June 4th 2016, 3:09am

ASCO Annual Meeting

Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.

June 4th 2016, 2:38am

ASCO Annual Meeting

A biosimilar version of trastuzumab demonstrated equivalent efficacy and safety to the FDA-approved branded drug in a randomized phase III study among patients with HER2-positive metastatic breast cancer.

June 4th 2016, 1:23am

ASCO Annual Meeting

The addition of capecitabine to standard adjuvant gemcitabine doubled 5-year overall survival (OS) rates for patients with pancreatic cancer whose tumors were surgically removed.

June 1st 2016, 7:41pm

ASCO Annual Meeting

Immunotherapy agents targeting the PD-1/PD-L1 pathway will be the most robust area for news at the 2016 ASCO Annual Meeting, but there will be much new data about recently approved and novel anticancer drugs for clinicians to digest.

May 31st 2016, 7:24pm

ASCO Annual Meeting

Research into 6 drugs scheduled to be presented during the upcoming 2016 ASCO Annual Meeting stand out as the most noteworthy abstracts on the docket this year because of their potential to influence clinical practice in the near future.

May 19th 2016, 3:11am

ASCO Annual Meeting

Forty percent of patients with advanced melanoma who started taking pembrolizumab during the clinical trial that led to its initial approval were still alive after 3 years, with many responders in remission even after stopping treatment.

May 19th 2016, 2:10am

ASCO Annual Meeting

Early findings from a phase III clinical trial suggest that patients with multiple myeloma who receive upfront autologous stem cell transplant survive longer without disease progression than those who receive chemotherapy alone.

May 19th 2016, 1:48am

ASCO Annual Meeting

Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.

May 19th 2016, 1:44am

ASCO Annual Meeting

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

May 19th 2016, 1:12am

ASCO Annual Meeting

Outcomes were significantly better in clinical trials that utilized a biomarker-based treatment selection strategy compared with non-personalized approaches.

May 12th 2016, 9:42am

AUA Annual Meeting

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

May 11th 2016, 4:55pm

AUA Annual Meeting

Major health policy implications follow findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial, after it was found that 80% of the control group reported at least one PSA test during the trial.

April 28th 2016, 8:05am

Oncology Nursing Society Congress

Dennise Geiger, RN, Regional Cancer Care Associates, Central Jersey Division, discusses difficulties nurses face when using telephone triage, and the plan that was developed to better streamline the process.